BACKGROUND: Elderly cancer patients commonly have renal function decline. This warrants particular caution during the administration of renally excreted cancer drugs or those with established nephrotoxicity. DESIGN: An International Society for Geriatric Oncology task force was formed to discuss treatment recommendations for this group of patients. RESULTS: Before drug therapy, the assessment and optimization of hydration status and evaluation of renal function is required. Serum creatinine alone is insufficient as a means of evaluating renal function, and creatinine clearance should at least be calculated in every patient by the abbreviated modification of diet in renal disease or Cockcroft-Gault equations. In the extremes of obesity and cachexia and at very high and low creatinine values, no single tool is really accurate. In these patients, the best estimate of glomerular filtration rate is provided by direct methods such as (51)Cr-EDTA or inulin measurement. Within each drug class, preference may be given to agents less likely to be influenced by renal clearance, which are minimally nephrotoxic, or for which appropriate methods of prevention for renal toxicity exist. Coadministration of known nephrotoxic drugs should be avoided or minimized. CONCLUSIONS: Future trials should be designed to present data in a way that allows evaluation of the contribution of renal function to toxicity and efficacy.
BACKGROUND: Elderly cancerpatients commonly have renal function decline. This warrants particular caution during the administration of renally excreted cancer drugs or those with established nephrotoxicity. DESIGN: An International Society for Geriatric Oncology task force was formed to discuss treatment recommendations for this group of patients. RESULTS: Before drug therapy, the assessment and optimization of hydration status and evaluation of renal function is required. Serum creatinine alone is insufficient as a means of evaluating renal function, and creatinine clearance should at least be calculated in every patient by the abbreviated modification of diet in renal disease or Cockcroft-Gault equations. In the extremes of obesity and cachexia and at very high and low creatinine values, no single tool is really accurate. In these patients, the best estimate of glomerular filtration rate is provided by direct methods such as (51)Cr-EDTA or inulin measurement. Within each drug class, preference may be given to agents less likely to be influenced by renal clearance, which are minimally nephrotoxic, or for which appropriate methods of prevention for renal toxicity exist. Coadministration of known nephrotoxic drugs should be avoided or minimized. CONCLUSIONS: Future trials should be designed to present data in a way that allows evaluation of the contribution of renal function to toxicity and efficacy.
Authors: Arti Hurria; Ilene S Browner; Harvey Jay Cohen; Crystal S Denlinger; Mollie deShazo; Martine Extermann; Apar Kishor P Ganti; Jimmie C Holland; Holly M Holmes; Mohana B Karlekar; Nancy L Keating; June McKoy; Bruno C Medeiros; Ewa Mrozek; Tracey O'Connor; Stephen H Petersdorf; Hope S Rugo; Rebecca A Silliman; William P Tew; Louise C Walter; Alva B Weir; Tanya Wildes Journal: J Natl Compr Canc Netw Date: 2012-02 Impact factor: 11.908
Authors: Stuart M Lichtman; Constance T Cirrincione; Arti Hurria; Aminah Jatoi; Maria Theodoulou; Antonio C Wolff; Julie Gralow; Daniel E Morganstern; Gustav Magrinat; Harvey Jay Cohen; Hyman B Muss Journal: J Clin Oncol Date: 2016-01-11 Impact factor: 44.544
Authors: Husain K Khambati; Toni K Choueiri; Christian K Kollmannsberger; Scott North; George A Bjarnason; Ulka N Vaishampayan; Lori Wood; Jennifer J Knox; Min-Han Tan; Mary J MacKenzie; Frede Donskov; Brian I Rini; Daniel Y C Heng Journal: Clin Genitourin Cancer Date: 2014-03-05 Impact factor: 2.872
Authors: Thuy Koll; Mackenzi Pergolotti; Holly M Holmes; Huibrie C Pieters; G J van Londen; Zachary A Marcum; Amy R MacKenzie; Christopher B Steer Journal: Curr Oncol Rep Date: 2016-08 Impact factor: 5.075